Quantcast

Latest drug discovery Stories

2014-07-02 23:11:19

InSilico Medicine, Inc. announces today: after decades of theoretical research and animal experimentation, the industry, academia and the policy makers will discuss the possible avenues for translating the leading laboratory discoveries into clinical practice. Baltimore, MD (PRWEB) July 02, 2014 Alex Zhavoronkov, PhD, CEO of InSilico Medicine, Inc. and Bhupinder Bhullar, PhD, the laboratory director of the Novartis Institute for Biomedical Research (NIBR) are co-organizing the...

2014-07-02 23:03:52

MarketOptimizer.org adds “Paralysis Global Clinical Trials Review, H1, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Paralysis. Dallas, Texas (PRWEB) July 02, 2014 Clinical trial report, “Paralysis Global Clinical Trials Review, H1, 2014″ provides data on the Paralysis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Paralysis. It includes an overview of the...

2014-07-01 23:07:01

This report studies the newborn screening market by test type, technology, product, and geography. http://www.marketsandmarkets.com/Market-Reports/newborn-screening-market-141676244.html (PRWEB) July 01, 2014 The "Newborn Screening Market by Test Type (Dried Blood Spot, Hearing Screening, CCHD), Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse-oximeter), Instrument, Accessories, Reagent & by Assay Kit – Global Forecast to 2019"...

2014-06-30 16:26:40

SANTA ROSA, Calif., June 30, 2014 /PRNewswire/ -- Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fourth quarter and fiscal year ended March 31, 2014. "We are poised to commence patient enrollment in the initial phase of our first human clinical trial using RUT58-60 in July 2014, and plan to complete our Phase 1/2 clinical trial in less than nine months," said Hoji Alimi, Chairman, CEO and CSO of Ruthigen. "We believe that the completion of our recent initial public...

2014-06-30 12:31:55

BUFFALO, N.Y. and SEOUL, South Korea, June 30, 2014 /PRNewswire/ -- Hanmi Pharmaceuticals announces a positive study on Oraxol® use in a Phase I/II clinical proof-of-concept study (Study HM-OXL-201) of Oraxol - an oral form of the approved drug paclitaxel, with HM30181, a highly potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. The study, entitled "A phase I-II clinical trial to determine the recommended dose and to assess the efficacy, safety and...

2014-06-30 11:35:43

Rockefeller University Without a steady supply of blood, neurons can't work. That's why one of the culprits behind Alzheimer's disease is believed to be the persistent blood clots that often form in the brains of Alzheimer's patients, contributing to the condition's hallmark memory loss, confusion and cognitive decline. New experiments in Sidney Strickland's Laboratory of Neurobiology and Genetics at Rockefeller University have identified a compound that might halt the progression of...

2014-06-30 04:21:39

LONDON and BOSTON, June 30, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is delighted to announce that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, has been invited to present at the Royal Society of Medicine Medical Innovations Summit. The event, which takes place on Saturday 5 July 2014 at The Royal Society of Medicine in London, UK, will feature presentations on pioneering...

2014-06-26 23:14:34

The webinar will focus on gaining more predictive results in anti-cancer drug discovery on July 10th, 2014. Yorba Linda, CA (PRWEB) June 26, 2014 PerkinElmer just announced that their new webinar, “More Predictive Results in Cell-Based Assays: Combining Target-Based & Phenotypic Approaches Using the New EnSight Plate Reader,” will feature guest speaker Dr. Philip Gribbon, the Chief Scientific Officer at the European ScreeningPort (ESP). Dr. Gribbon has incorporated Perkin...

2014-06-26 16:23:38

Paper Addresses Challenges and Explores Opportunities to Stimulate Repurposing of FDA-Approved Drugs for Alzheimer's, Parkinson's and Related Diseases NEW YORK, June 26, 2014 /PRNewswire-USNewswire/ -- A new peer-reviewed publication from the Alzheimer's Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug...

2014-06-26 08:29:00

Expansion to Accelerate Critical Research with Goal of Bringing Novel Therapies to Patients Faster NEW YORK, June 26, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and OnDeckBiotech announced today a strategic partnership to provide a new platform technology for ADDF ACCESS. ADDF ACCESS is an open access database that provides a network of contract research organizations (CROs), drug development consultants and educational resources focused for...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related